CTC Alternative Strategies’s Gilead Sciences GILD Stock Holding History

CTC Alternative Strategies’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$379K	Buy	+3,000	New	+$395K	0.55%	41
2026 Q1	–	Sell	-9,100	Closed	-$1.12M	–	106
2025 Q4	$1.12M	Buy	+9,100	New	+$1.11M	2.09%	13
2025 Q3	–	Sell	-7,700	Closed	-$854K	–	136
2025 Q2	$854K	Buy	7,700 +700	+10%	+$74.5K	0.75%	34
2025 Q1	$784K	Buy	+7,000	New	+$722K	0.96%	24
2024 Q3	–	Sell	-6,014	Closed	-$413K	–	121
2024 Q2	$413K	Buy	+6,014	New	+$401K	0.18%	135

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CTC Alternative Strategies's GILD Position: Q2 2026 in Review

CTC Alternative Strategies opened a new position in Gilead Sciences (GILD) in Q2 2026: 3,000 shares worth $379K. The stake represents 0.55% of the portfolio and ranks #41 among its holdings. This is a return to the name: CTC Alternative Strategies previously reported a position in GILD as recently as Q4 2025.

CTC Alternative Strategies first reported a position in GILD in Q2 2024 and has held it in 5 quarters since. The position peaked at $1.12M in Q4 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

CTC Alternative Strategies held 3,000 shares of Gilead Sciences worth $379K as of Q2 2026.
Gilead Sciences was a new CTC Alternative Strategies position in Q2 2026.
Gilead Sciences made up 0.55% of CTC Alternative Strategies's portfolio in Q2 2026, its #41 holding.
CTC Alternative Strategies first reported a position in Gilead Sciences in Q2 2024 and has held it in 5 quarters since.
CTC Alternative Strategies's Gilead Sciences position peaked at $1.12M in Q4 2025.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on CTC Alternative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.